Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors

被引:68
|
作者
D'Agostino, Ralph B., Sr. [1 ]
Collins, Sylva H. [2 ]
Pencina, Karol M. [1 ]
Kean, Yin
Gorbach, Sherwood [2 ]
机构
[1] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[2] Cubist Pharmaceut, Lexington, MA USA
关键词
Clostridium difficile infection; CDI; fidaxomicin; vancomycin; INTEGRATED DISCRIMINATION; NET RECLASSIFICATION; VANCOMYCIN; EPIDEMIOLOGY; FIDAXOMICIN; DIARRHEA; DISEASE; METRONIDAZOLE; MANAGEMENT; CARE;
D O I
10.1093/cid/ciu107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade. Although patients respond well to medical therapy such as vancomycin, 20%-30% of patients treated suffer a recurrence of CDI. Methods. We developed a simple/practical scoring rule (logistic regression model) for recurrent CDI using data from 2 large phase 3 clinical trials. Seventy-seven baseline CDI factors were classified: demographics, comorbidity, medications, vital signs, laboratory tests, severity, and symptoms. Predictors with the highest discrimination in each class (using receiver operating characteristics curve) were selected. For the final model, stepwise selection was performed. Discrimination, calibration, and internal validation were used to assess the model. Results. The final model with a simple scoring rule was developed. It includes 4 independent risk factors that are readily available when the patient makes initial contact: age (<75 vs >= 75 years), number of unformed bowel movements during previous 24 hours (<10 vs >= 10), serum creatinine leves (< 1.2 mg/dL vs >= 1.2 mg/dL) and prior episode of CDI (yes vs no). In addition, the model includes choice of treatment (vancomycin or fidaxomicin). Conclusions. The prediction model for recurrence may be useful for treatment decision.
引用
收藏
页码:1386 / 1393
页数:8
相关论文
共 50 条
  • [1] Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel
    Na'amnih, Wasef
    Adler, Amos
    Miller-Roll, Tamar
    Cohen, Dani
    Carmeli, Yehuda
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (07) : 1281 - 1288
  • [2] Clinical and demographic profile and risk factors for Clostridium difficile infection
    Carvajal, Carlos
    Pacheco, Carlos
    Jaimes, Fabian
    BIOMEDICA, 2017, 37 (01): : 53 - 61
  • [3] Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention
    Song, Jung Hoon
    Kim, You Sun
    GUT AND LIVER, 2019, 13 (01) : 16 - 24
  • [4] Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
    Johnson, Stuart
    JOURNAL OF INFECTION, 2009, 58 (06) : 403 - 410
  • [5] Novel Risk Factors for Recurrent Clostridium difficile Infection in Children
    Nicholson, Maribeth R.
    Thomsen, Isaac P.
    Slaughter, James C.
    Creech, C. Buddy
    Edwards, Kathryn M.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2015, 60 (01) : 18 - 22
  • [6] Risk factors for recurrent Clostridium difficile infection among patients in the Clinical Centre of Vojvodina, Serbia: a retrospective clinical trial
    Kovacevic, Nadica
    Doder, Radoslava
    Preveden, Tomislav
    Pete, Maria
    VOJNOSANITETSKI PREGLED, 2019, 76 (04) : 392 - 397
  • [7] Fecal Transplantation, Through Colonoscopy, Is Effective Therapy for Recurrent Clostridium difficile Infection
    Mattila, Eero
    Uusitalo-Seppala, Raija
    Wuorela, Maarit
    Lehtola, Laura
    Nurmi, Heimo
    Ristikankare, Matti
    Moilanen, Veikko
    Salminen, Kimmo
    Seppala, Maaria
    Mattila, Petri S.
    Anttila, Veli-Jukka
    Arkkila, Perttu
    GASTROENTEROLOGY, 2012, 142 (03) : 490 - 496
  • [8] Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
    Gerding, Dale N.
    Kelly, Ciaran P.
    Rahav, Galia
    Lee, Christine
    Dubberke, Erik R.
    Kumar, Princy N.
    Yacyshyn, Bruce
    Kao, Dina
    Eves, Karen
    Ellison, Misoo C.
    Hanson, Mary E.
    Guris, Dalya
    Dorr, Mary Beth
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (05) : 649 - 656
  • [9] Can we identify patients at high risk of recurrent Clostridium difficile infection?
    Kelly, C. P.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 : 21 - 27
  • [10] Clostridium Difficile Infection: Risk Factors, Diagnosis and Management
    Christina M. Surawicz
    Current Treatment Options in Gastroenterology, 2015, 13 (1) : 121 - 129